Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.62 |
| ▸ | FAAH | O00519 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LPL | P06858 | 1/20 | 0.43 |
| ▸ | LIPC | P11150 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7043932 | 0.85 | LPL (0.56) | MGLLFAAHMAPTSMN1; SMN2THRB | |
| SCHEMBL7043167 | 0.84 | MGLL (0.56) | MGLLFAAHMAPTABHD16ALPL | |
| SCHEMBL7653362 | 0.83 | FAAH (0.49) | MGLLFAAHMAPTSMN1; SMN2ABHD16A | |
| SCHEMBL7046445 | 0.82 | MGLL (0.62) | MGLLFAAHMAPTSMN1; SMN2HTT | |
| SCHEMBL7571649 | 0.82 | MGLL (0.72) | MGLLFAAHMAPTSMN1; SMN2ABHD16A | |
| SCHEMBL7042329 | 0.80 | MGLL (0.61) | MGLLFAAHMAPTSMN1; SMN2THRB | |
| SCHEMBL7045989 | 0.79 | MGLL (0.66) | MGLLFAAHMAPTSMN1; SMN2ABHD16A | |
| SCHEMBL6615026 | 0.78 | MGLL (0.75) | MGLLFAAHMAPTSMN1; SMN2ABHD16A | |
| SCHEMBL7045595 | 0.77 | MGLL (0.51) | MGLLFAAHMAPTABHD16ATP53 | |
| SCHEMBL29499689 | 0.77 | MGLL (1.00) | MGLLFAAHSMN1; SMN2ABHD16ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946574-B1 | 3-ARYL SUBSTITUTED INDENYL CONTAINING METAL COMPLEXES AND POLYMERIZATION PROCESS | DOW CHEMICAL CO (US) | 2002-02-13 | — | — | EP | claimed |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | disclosed |
| US-6369088-B2 | ANTIDIABETIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | CNR1, PTGER1, CNR2 | MGLL 1542/4885FAAH 46/4885MAPT 4852/4885 |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | PNLIP, CEL, LIPE | MGLL 10/4885FAAH 142/4885MAPT 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.